[Tixagevimab/cilgavimab (COVID-19) - benefit assessment according to § 35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004352
Original Title: Tixagevimab/Cilgavimab (COVID-19)
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • COVID-19
  • COVID-19 Drug Treatment
  • SARS-CoV-2
  • Coronavirus Infections
  • Antibodies, Monoclonal
  • Drug Combinations
  • Antibodies, Neutralizing
  • Antiviral Agents
  • Tixagevimab
  • Cilgavimab
  • COVID-19
  • Benefit Assessment
  • NCT04723394
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.